STOCK TITAN

Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Solid Biosciences Inc. (SLDB) to present at Piper Sandler Healthcare Conference on November 30, 2023
Positive
  • None.
Negative
  • None.

CHARLESTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Piper Sandler Healthcare Conference on Thursday, November 30, 2023, at 1:00 pm ET.

A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for 30 days on the Events page.

Institutional investors interested in meeting with management during the conference may reach out to their Piper Sandler representatives.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates and neuromuscular and cardiac programs, including SGT-003, for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, AVB-202-TT for the treatment of Friedreich’s ataxia, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Contact:
Leah Monteiro
VP, Investor Relations & Communications
617-766-3430
lmonteiro@solidbio.com


The presentation is scheduled for Thursday, November 30, 2023, at 1:00 pm ET.

The live webcast will be available on the Events page of the Investors section of the Company website or by clicking here.

The webcast replay will be archived for 30 days on the Events page.

Institutional investors interested in meeting with management may reach out to their Piper Sandler representatives.
Solid Biosciences Inc.

NASDAQ:SLDB

SLDB Rankings

SLDB Latest News

SLDB Stock Data

334.90M
18.01M
0.79%
75.88%
2.44%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
CHARLESTOWN

About SLDB

solid biosciences (solid) is a cambridge, ma based biotech company singularly focused on developing treatments and cures for duchenne muscular dystrophy (dmd). solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of dmd.